⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
globenewswire.com
AIM
Pancreatic Cancer Diagnostics Research Report 2026
globenewswire.com
NVDA
AIM
ILMN
GH
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
globenewswire.com
AIM